Long‑term outcomes following adjuvant endocrine therapy in breast cancer patients with a positive‑to‑negative change of hormone receptor status following neoadjuvant chemotherapy

Wu,Jia  Yi; Chen,Wei  Guo; Chen,Xiao  Song; Huang,Ou; He,Jian  Rong; Zhu,Li; Li,Yafen; Shen,Kun  Wei

doi:10.3892/mco.2014.365

Long‑term outcomes following adjuvant endocrine therapy in breast cancer patients with a positive‑to‑negative change of hormone receptor status following neoadjuvant chemotherapy

Authors:
- Jia Yi Wu
- Wei Guo Chen
- Xiao Song Chen
- Ou Huang
- Jian Rong He
- Li Zhu
- Yafen Li
- Kun Wei Shen
View Affiliations

Affiliations: Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China
Published online on: July 31, 2014 https://doi.org/10.3892/mco.2014.365
Pages: 997-1002

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate whether breast cancer patients with changes from positive to negative in the hormone receptor following neoadjuvant chemotherapy (NAC) could benefit from adjuvant endocrine therapy (ET). Between December 2000 and November 2010, 97 eligible patients with a positive‑to‑negative switch of the hormone receptor status following NAC were identified. All the patients were categorized into two groups on the basis of the administration of ET: 57 ET‑administered and 40 ET‑naïve patients. Survival analyses were performed to examine the prognostic value of ET administration, as well as other clinical and pathological variables. The administration of ET was associated with a significantly improved disease‑free survival (DFS) (P=0.018) in patients with a positive‑to‑negative switch of the hormone receptor status. The 5‑year DFS rates were 77.0 and 55.5% in ET‑administered and ET‑naïve patients, respectively. The 5‑year overall survival (OS) rate for ET‑administered was also higher than that of the ET‑naïve patients (81.3 vs. 72.7%, P=0.053), but the difference between the two groups did not reach a statistical significance. The present study revealed that patients with the hormone receptor that was altered from positive to negative following NAC benefit from ET, and the hormone receptor status should be evaluated not only in specimens obtained during post‑NAC surgery, but also in specimens biopsied prior to NAC.

View Figures

View References

1	Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, et al: International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer; Cremona, Italy. 2010; J Natl Cancer Inst Monogr. 2011. pp. 147–151. 2011, View Article : Google Scholar
2	Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, et al: Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 19:1508–1516. 2012. View Article : Google Scholar : PubMed/NCBI
3	Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright D, Allen SA, Dove J and Wilson GD: Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 92:147–155. 2005. View Article : Google Scholar : PubMed/NCBI
4	Hirata T, Shimizu C, Yonemori K, Hirakawa A, Kouno T, Tamura K, Ando M, Katsumata N and Fujiwara Y: Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer. 101:1529–1536. 2009. View Article : Google Scholar : PubMed/NCBI
5	Jain V, Landry M and Levine EA: The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma. Am Surg. 62:162–165. 1996.PubMed/NCBI
6	Tacca O, Penault-Llorca F, Abrial C, Mouret-Reynier MA, Raoelfils I, Durando X, Achard JL, Gimbergues P, Curé H and Chollet P: Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist. 12:636–643. 2007. View Article : Google Scholar
7	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
8	Chen X, Yuan Y, Gu Z and Shen K: Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis. Breast Cancer Res Treat. 134:957–967. 2012. View Article : Google Scholar : PubMed/NCBI
9	Zhang N, Moran MS, Huo Q, Haffty BG and Yang Q: The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis. Cancer Invest. 29:594–598. 2011. View Article : Google Scholar : PubMed/NCBI
10	van de Ven S, Smit VT, Dekker TJ, Nortier JW and Kroep JR: Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev. 37:422–430. 2011.PubMed/NCBI
11	Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ; Panel members. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar
12	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
13	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI
14	Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, Shao ZM, Shen ZZ and Shen KW: Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy. Oncol Rep. 23:1213–1220. 2010.PubMed/NCBI